SEC Form 4 · accession 0000897204-18-000028
INTERCEPT PHARMACEUTICALS, INC. · ICPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Genextra S.p.A.
10% Owner
Period of report
Apr 9, 2018
Accepted (ET)
Apr 9, 2018 · 5:20 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001270073
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stock, par value $0.001 per shareF1 | Apr 9, 2018 | P | 390,625 | $64.00 | A | 6,845,578 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares of common stock purchased by Genextra S.p.A. in a private offering that was completed on April 9, 2018.